Previous 10 | Next 10 |
Gainers: China SXT Pharmaceuticals (SXTC) +37%, Trinity Biotech (TRIB) +11%, Moderna (MRNA) +9%, Aptevo Therapeutics (APVO) +9%, Apollo Medical (AMEH) +4%.Losers: FibroGen (FGEN) -45%, Neptune Wellness Solutions (NEPT) -20%, Atossa Therapeutic...
Atossa Therapeutics is defying the biotech bear market - shares are up ~400% across the past 6 months. The company has an opportunity in breast cancer therapy with Endoxifen - a metabolite of 40-year old therapy Tamoxifen, targeting the prevention, neoadjuvant and treatment settings. ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips There are a couple of ways that market participants can approach clinical-stage biopharmaceutical firm Atossa Therapeutics (NASDAQ: ATOS ). They can try to trade ATOS stock for quick gains or they can buy and hol...
Physician-Scientist Steven Quay and an International Team of Scientists and Investigators Provide Science-Based Analysis of the Origin of COVID-19 to the US Congress PR Newswire SEATTLE , July 15, 2021 /PRNewswire/ -- An international team of scientists and data ...
Atossa Therapeutics ([[ATOS]] +3.7%) has received regulatory approval from Human Research Ethics Committee ((HREC)) to open a clinical study of AT-H201, being developed as an inhalation therapy for moderately to severely-ill hospitalized COVID-19 patients, in Australia.The...
Nebulized formulation being developed to improve lung function in both active-disease COVID-19 patients and “Long Haul” patients with post-infection pulmonary disease SEATTLE, July 07, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Clinical-stage biopharmaceutical firm Atossa Therapeutics (NASDAQ: ATOS ) primarily focuses on two diseases: breast cancer and Covid-19. Hence, ATOS stock holders are supporting a company that’s potentiall...
Companies engaged in developing therapies for Alzheimer's disease were among the best performing biotech stocks in the first half of the year.Cassava Sciences ([[SAVA]] -1.7%) was the best performing biotech stock in the half, with a return in the period of 1166%.A phase 3 trial of its Alzhei...
After a blistering June rally, we see a temporary top here probably back to around the $4 level. Implied volatility remains significantly elevated. We are going to get our move sooner rather than later. We are controlling risk by rolling puts out in time. Significant upside potent...
Shares of Atossa Therapeutics Inc. (NASDAQ:ATOS) traded today at $6.86, eclipsing its 52-week high. Approximately 7.2 million shares have changed hands today, as compared to an average 30-day volume of 18.4 million shares. In the past 52 weeks, Atossa Therapeutics Inc. share prices are b...
News, Short Squeeze, Breakout and More Instantly...
Atossa Therapeutics Inc. Company Name:
ATOS Stock Symbol:
NASDAQ Market:
Atossa Therapeutics Inc. Website:
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully...